Xenon Pharmaceuticals Inc Market Cap ($2.89 Billion)
Market Cap & Net Worth: Xenon Pharmaceuticals Inc (XENE)
Xenon Pharmaceuticals Inc market cap. Xenon Pharmaceuticals Inc (NASDAQ:XENE) has a market capitalization of $2.89 Billion ($2.89 Billion) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #4841 globally and #1678 in its home market, demonstrating a 2.49% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Xenon Pharmaceuticals Inc's stock price $37.41 by its total outstanding shares 77275005 (77.28 Million). Also see Xenon Pharmaceuticals Inc cash flow conversion for how efficiently the company converts equity into cash flow.
Xenon Pharmaceuticals Inc Market Cap History (2015–2026)
Xenon Pharmaceuticals Inc market cap history from 2015 to 2026. Data shows growth from $621.29 Million to $2.89 Billion (13.81% CAGR). Check Xenon Pharmaceuticals Inc (XENE) share price today for real-time trading data and today's change.
Index Memberships
Xenon Pharmaceuticals Inc is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.11% | #131 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.01% | #565 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.16% | #84 of 263 |
Weight: Xenon Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Xenon Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Xenon Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore XENE net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
461.80x
Xenon Pharmaceuticals Inc's market cap is 461.80 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $595.02 Million | $1.80 Million | -$23.00 Million | 330.02x | N/A |
| 2017 | $218.30 Million | $311.00K | -$30.70 Million | 701.94x | N/A |
| 2019 | $1.01 Billion | $6.83 Million | -$41.59 Million | 148.35x | N/A |
| 2020 | $1.19 Billion | $32.17 Million | -$28.84 Million | 36.95x | N/A |
| 2021 | $2.41 Billion | $18.44 Million | -$78.88 Million | 130.94x | N/A |
| 2022 | $3.05 Billion | $9.43 Million | -$125.37 Million | 322.98x | N/A |
| 2025 | $3.46 Billion | $7.50 Million | -$345.91 Million | 461.80x | N/A |
Competitor Companies of XENE by Market Capitalization
Companies near Xenon Pharmaceuticals Inc in the global market cap rankings as of November 1, 2026. Also see Xenon Pharmaceuticals Inc (XENE) total assets for a full breakdown of the balance sheet.
Key companies related to Xenon Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #182 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #371 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #412 globally with a market cap of $68.91 Billion USD ( AU$97.38 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #495 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #182 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $558.88 |
| #371 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $927.89 |
| #412 | CSL Ltd | AU:CSL | $68.91 Billion | AU$200.73 |
| #495 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $221.72 |
Market Capitalization of Xenon Pharmaceuticals Inc (2015–2026)
Market capitalization of Xenon Pharmaceuticals Inc from 2015 to today. Between 2015 and today, Xenon Pharmaceuticals Inc's market cap moved from $621.29 Million to $ 2.89 Billion, with a yearly change of 13.81%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.89 Billion | -16.53% |
| 2025 | $3.46 Billion | +14.34% |
| 2024 | $3.03 Billion | -14.89% |
| 2023 | $3.56 Billion | +16.81% |
| 2022 | $3.05 Billion | +26.22% |
| 2021 | $2.41 Billion | +103.12% |
| 2020 | $1.19 Billion | +17.32% |
| 2019 | $1.01 Billion | +107.77% |
| 2018 | $487.61 Million | +123.36% |
| 2017 | $218.30 Million | -63.31% |
| 2016 | $595.02 Million | -4.23% |
| 2015 | $621.29 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Xenon Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.89 Billion USD |
| MoneyControl | $2.89 Billion USD |
| MarketWatch | $2.89 Billion USD |
| marketcap.company | $2.89 Billion USD |
| Reuters | $2.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Xenon Pharmaceuticals Inc
Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizure… Read more